Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGFR BATs in Newly Diagnosed Glioblastoma
NCT03344250Phase 1Completed
- Sponsor
- University of Virginia
- Start
- Mar 2018
- Primary completion
- Dec 2021
- Modality
- Bispecific Antibodies, Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 1, open-label trial of EGFR BATs in glioblastoma (GBM) (2 arms), sponsored by University of Virginia. Primary endpoint: Maximum Tolerated Dose. Started Mar 2018; status: completed.
02
Drugs
EGFR BATs
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03344250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03344250.